Schwab Charles Investment Management Inc. boosted its position in shares of Johnson & Johnson (NYSE:JNJ) by 1.8% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 11,150,339 shares of the company’s stock after buying an additional 201,703 shares during the period. Johnson & Johnson makes up approximately 1.4% of Schwab Charles Investment Management Inc.’s portfolio, making the stock its 4th largest position. Schwab Charles Investment Management Inc.’s holdings in Johnson & Johnson were worth $1,388,775,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. Lau Associates LLC increased its stake in Johnson & Johnson by 12.8% in the first quarter. Lau Associates LLC now owns 46,878 shares of the company’s stock worth $5,839,000 after buying an additional 5,335 shares in the last quarter. Loomis Sayles & Co. L P increased its stake in Johnson & Johnson by 396.7% in the fourth quarter. Loomis Sayles & Co. L P now owns 110,823 shares of the company’s stock worth $12,768,000 after buying an additional 88,510 shares in the last quarter. Jackson Grant Investment Advisers Inc. increased its stake in Johnson & Johnson by 7.3% in the fourth quarter. Jackson Grant Investment Advisers Inc. now owns 14,124 shares of the company’s stock worth $1,627,000 after buying an additional 957 shares in the last quarter. Burke & Herbert Bank & Trust Co. increased its stake in Johnson & Johnson by 2.6% in the first quarter. Burke & Herbert Bank & Trust Co. now owns 47,330 shares of the company’s stock worth $5,895,000 after buying an additional 1,218 shares in the last quarter. Finally, Independent Advisor Alliance purchased a new stake in Johnson & Johnson during the fourth quarter worth $4,035,000. 66.06% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson (NYSE JNJ) traded down 0.26% during mid-day trading on Thursday, reaching $132.88. 530,201 shares of the company traded hands. Johnson & Johnson has a 12-month low of $109.32 and a 12-month high of $137.08. The stock has a market capitalization of $356.65 billion, a price-to-earnings ratio of 22.48 and a beta of 0.78. The company’s 50-day moving average is $133.23 and its 200-day moving average is $126.11.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, July 18th. The company reported $1.83 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.79 by $0.04. The company had revenue of $18.84 billion for the quarter, compared to analysts’ expectations of $18.94 billion. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The firm’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same period in the prior year, the firm earned $1.74 earnings per share. Equities analysts predict that Johnson & Johnson will post $7.18 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 12th. Investors of record on Tuesday, August 29th will be paid a $0.84 dividend. The ex-dividend date of this dividend is Friday, August 25th. This represents a $3.36 annualized dividend and a yield of 2.52%. Johnson & Johnson’s payout ratio is 56.76%.

COPYRIGHT VIOLATION WARNING: “Schwab Charles Investment Management Inc. Purchases 201,703 Shares of Johnson & Johnson (NYSE:JNJ)” was originally published by Daily Political and is the property of of Daily Political. If you are viewing this piece on another publication, it was stolen and republished in violation of international copyright and trademark law. The original version of this piece can be viewed at https://www.dailypolitical.com/2017/08/10/schwab-charles-investment-management-inc-purchases-201703-shares-of-johnson-johnson-nysejnj.html.

A number of analysts have weighed in on JNJ shares. Morgan Stanley increased their target price on shares of Johnson & Johnson from $135.00 to $140.00 and gave the company an “overweight” rating in a research report on Wednesday, July 5th. BidaskClub downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 1st. Vetr downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating and set a $128.54 target price for the company. in a research report on Monday, May 1st. Jefferies Group LLC reissued a “hold” rating and set a $140.00 target price on shares of Johnson & Johnson in a research report on Friday, June 16th. Finally, Zacks Investment Research downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Friday, July 21st. Three analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. Johnson & Johnson currently has an average rating of “Hold” and a consensus price target of $133.72.

In other news, VP Dominic J. Caruso sold 82,591 shares of the stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $136.72, for a total value of $11,291,841.52. Following the sale, the vice president now directly owns 226,693 shares of the company’s stock, valued at $30,993,466.96. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Paulus Stoffels sold 102,692 shares of the stock in a transaction on Monday, July 24th. The stock was sold at an average price of $133.14, for a total value of $13,672,412.88. Following the completion of the sale, the vice president now directly owns 230,342 shares in the company, valued at $30,667,733.88. The disclosure for this sale can be found here. 0.19% of the stock is owned by corporate insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.